
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN – Free Report) – Equities research analysts at Noble Financial boosted their FY2026 earnings per share (EPS) estimates for Eledon Pharmaceuticals in a research report issued to clients and investors on Monday, November 16th. Noble Financial analyst R. Leboyer now forecasts that the company will post earnings per share of ($0.58) for the year, up from their previous forecast of ($0.74). The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.74) per share. Noble Financial also issued estimates for Eledon Pharmaceuticals’ Q4 2026 earnings at ($0.20) EPS.
Eledon Pharmaceuticals (NASDAQ:ELDN – Get Free Report) last announced its earnings results on Friday, November 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01.
A number of other equities analysts have also issued reports on ELDN. Wall Street Zen raised Eledon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday. Rodman & Renshaw began coverage on shares of Eledon Pharmaceuticals in a research report on Tuesday, July 21st. They set a “buy” rating and a $12.00 price target for the company. Finally, Weiss Ratings upgraded shares of Eledon Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a research note on Monday, November 9th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $12.00.
View Our Latest Stock Report on ELDN
Eledon Pharmaceuticals Stock Up 0.5%
Shares of NASDAQ ELDN opened at $1.98 on Wednesday. Eledon Pharmaceuticals has a fifty-two week low of $1.35 and a fifty-two week high of $4.49. The business has a 50 day moving average price of $2.52 and a two-hundred day moving average price of $3.11. The firm has a market cap of $167.23 million, a PE ratio of -2.71 and a beta of 0.95.
Hedge Funds Weigh In On Eledon Pharmaceuticals
A number of hedge funds have recently bought and sold shares of ELDN. BlackRock Inc. acquired a new position in shares of Eledon Pharmaceuticals in the 2nd quarter worth approximately $20,188,000. AWM Investment Company Inc. bought a new stake in shares of Eledon Pharmaceuticals in the 2nd quarter valued at approximately $4,334,000. Bank of America Corp DE bought a new stake in shares of Eledon Pharmaceuticals in the 2nd quarter valued at approximately $3,479,000. ADAR1 Capital Management LLC acquired a new stake in shares of Eledon Pharmaceuticals during the 2nd quarter valued at approximately $2,552,000. Finally, Triumph Capital Management acquired a new stake in shares of Eledon Pharmaceuticals during the 2nd quarter valued at approximately $1,196,000. 56.77% of the stock is currently owned by institutional investors and hedge funds.
About Eledon Pharmaceuticals
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for serious diseases involving the immune system. The company’s research focuses on modulating immune responses to help address conditions such as organ transplant rejection and amyotrophic lateral sclerosis (ALS). Its lead investigational product, tegoprubart, is an antibody that targets CD40 ligand, a protein involved in immune-system activation. Eledon is studying tegoprubart as a potential treatment to reduce rejection following organ transplantation and in research involving ALS.
Featured Stories
- Five stocks we like better than Eledon Pharmaceuticals
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Eledon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eledon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
